LAPIX Therapeutics Appoints Nimbus CEO Abbas Kazimi to Board as Oral TIM-3/TIM-4 Agonist Advances Through Phase 1b Trials
核心洞察
LAPIX Therapeutics (搜索) has appointed Abbas Kazimi, CEO of Nimbus Therapeutics (搜索), to its board of directors as the company advances its lead autoimmune candidate through clinical development.
LPX-TI641, an oral TIM-3 (搜索)/TIM-4 (搜索) agonist, is being evaluated in Phase 1b studies across more than 75 patients with rheumatoid arthritis (搜索) and atopic dermatitis (搜索) at two dose levels for up to three months.
The company plans to expand clinical development into additional autoimmune disease indications beyond the current Phase 1b programs.
LAPIX Therapeutics (搜索), a clinical-stage biotechnology company, has appointed Abbas Kazimi, chief executive officer of Nimbus Therapeutics (搜索), to its board of directors. The appointment comes as the company advances LPX-TI641, its oral TIM-3 (搜索)/TIM-4 (搜索) agonist candidate, through Phase 1b clinical trials in rheumatoid arthritis (搜索) (RA) and atopic dermatitis (搜索) (AD).
Kazimi brings more than two decades of biotechnology leadership experience spanning company building, corporate strategy, financing, and drug development. As CEO of Nimbus Therapeutics (搜索), he has overseen the advancement of a pipeline of precision medicines targeting diseases with significant unmet medical needs.
"LAPIX is pursuing a differentiated approach to autoimmune disease at a time when patients and physicians continue to need better therapies that can deliver a meaningful and durable benefit," said Kazimi. "The company's TIM-3 (搜索)/TIM-4 (搜索) agonist platform has the potential to open a new therapeutic path and redefine how autoimmune diseases are treated, and the emerging clinical progress is particularly compelling."
Clinical Program and Pipeline Expansion
LAPIX is currently evaluating LPX-TI641 in more than 75 patients across two different dose levels, with treatment periods of up to three months in the ongoing Phase 1b studies. The company also plans to further expand clinical development into additional autoimmune disease indications beyond RA and AD.
Anas Fathallah, chief executive officer of LAPIX Therapeutics (搜索), noted that Kazimi's experience scaling innovative biotechnology companies and guiding transformative therapies through development will be invaluable as the company progresses through this phase of growth. "As we advance our lead program through Phase 1b studies in RA and AD, his experience scaling innovative biotechnology companies and guiding transformative therapies through development will be invaluable," Fathallah said.
Mechanism of Action and Therapeutic Rationale
LAPIX is developing therapies designed to selectively target pathogenic immune cells that drive autoimmune disease while preserving broader immune function. The company believes this mechanism could represent a paradigm shift beyond conventional immunosuppressive therapies by delivering deep and durable disease control without the immunosuppressive side effects associated with other autoimmune treatments.
The TIM-3 (搜索)/TIM-4 (搜索) agonist platform represents what the company describes as a first-in-class oral approach to immune regulation. By selectively eliminating disease-driving immune cells, the lead therapeutic aims to deliver durable remissions and improved outcomes for patients living with chronic autoimmune conditions.